76Bio is a biotechnology company that develops therapies for patients with life-threatening diseases.
76Bio has raised $10.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2022.
76Bio's investors include Polaris Partners.
76Bio is headquartered in New York, United States.
76Bio is a biotechnology company that develops therapies for patients with life-threatening diseases.
76Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"76Bio — Funding & Investors." VCBacked, January 7, 2022, https://www.vcbacked.co/company/76bio. Accessed August 13, 2026.
VCBacked. (2022). 76Bio — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/76bio
{{cite web |title=76Bio — Funding & Investors |url=https://www.vcbacked.co/company/76bio |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated